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Accumulation of advanced oxidation protein
products induces podocyte apoptosis and
deletion through NADPH-dependent mechanisms
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The accumulation of plasma advanced oxidation protein
products (AOPPs) is prevalent in diverse disorders such as
diabetes, metabolic syndromes, and chronic kidney disease.
To study whether accumulated AOPPs have an important
role in the progression of proteinuria and glomerulosclerosis,
we chronically treated normal Sprague–Dawley rats with
AOPP-modified rat serum albumin. Podocyte apoptosis
was significantly increased coincident with the onset of
albuminuria and preceded significant losses of glomerular
podocytes. Increasing the amount of AOPPs in the media
of conditionally immortalized podocytes rapidly triggered
the production of intracellular superoxide by activation
of NADPH oxidase and this, in turn, led to an upregulation
of p53, Bax, caspase 3 activity, and apoptosis. Chronic
inhibition of NADPH oxidase by apocynin prevented
podocyte apoptosis, ameliorated podocyte depletion, and
decreased albuminuria in AOPP-challenged rats. Our
study demonstrates that accumulation of AOPPs promotes
NADPH oxidase–dependent podocyte depletion by a p53-Bax
apoptotic pathway both in vivo and in vitro.
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Progression to renal parenchymal damage and end-stage
renal disease, which seems to be largely independent of the
initial insults, is the common pathway for chronic kidney
disease (CKD) in both animals and humans.1,2 The key event
of the pathway is the impairment of glomerular permeability
to proteins, which permits excessive amounts of proteins to
reach the lumen of the proximal tubule and contributes to
renal interstitial injury by activating inflammatory and
fibrogenic cascades.3,4
Glomerular visceral epithelial cell, or podocyte, is one of
the major cell types in the glomerulus. The podocyte forms
a critical part of the glomerular filtration barrier and func-
tions to prevent urinary protein leakage and to maintain
glomerular capillary loop integrity.5 Podocyte depletion leads
to areas of denuded glomerular basement membrane,
culminating in proteinuria and development of glomerulo-
sclerosis.6 There is a growing body of literature showing that
podocyte loss is related to increasing proteinuria and
contributes to the progression of kidney disease in both
diabetic and nondiabetic CKD.7–13
Numerous factors have been implicated in the patho-
genesis of podocyte injury and depletion: hyperglycemia,
angiotensin II, reactive oxygen species, and transforming
growth factor-b have been extensively characterized.14–18
Recently, a family of oxidized protein compounds, termed
‘advanced oxidation protein products’ (AOPPs), has emerged
as a novel class of renal pathogenic mediators. AOPPs are
a class of dityrosine-containing protein products formed
during oxidative stress and carried mainly by albumin
in vivo.19,20 Accumulation of plasma AOPPs was first
identified in patients who underwent dialysis 19 and was
subsequently found in subjects with diabetes,21,22 metabolic
syndrome,23 and nondiabetic CKD.20 Our recent studies have
shown that chronic accumulation of plasma AOPPs signif-
icantly increases urinary protein excretion and accelerates
glomerulosclerosis in a remnant kidney model.24 An increase
in the concentration of plasma AOPPs to the level that
has been found in diabetic patients increases urinary
excretion of albumin in both normal and streptozotocin-
induced diabetic rats.24,25 Consistent with these observations,
data from a clinical study have shown that plasma AOPP level
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is a strong predictor for the prognosis of IgA nephropathy.26
Although these observations suggest that AOPP accumula-
tion has an important role in the progression of proteinuria
and glomerulosclerosis, the underlying cellular and molecular
mechanism(s) have not been clarified. It remains unknown
whether AOPPs affect structure and function of the podocyte.
Two underlying mechanisms for podocyte loss are apop-
tosis and detachment. Apoptosis in glomerular cells has been
demonstrated in animal models as well as in patients with
chronic renal insufficiency, diabetes, and hypertension nephro-
sclerosis,27–30 in which the accumulation of AOPPs is impli-
cated. Therefore, this study was designed to determine the
contribution of AOPPs to podocyte loss. Our data show that
the accumulation of AOPPs results in podocyte loss through
the induction of apoptosis. AOPP-induced podocyte apoptosis
is mainly mediated by the nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase-dependent superoxide genera-
tion, which activates the p53–Bcl-2-associated X (Bax)–caspase-
3 proapoptotic pathway.
RESULTS
Chronic administration of AOPPs increased urinary albumin
and 8-hydroxydeoxyguanosine excretion
To examine the renal pathogenic effects of AOPPs in vivo,
normal Sprague–Dawley rats were randomly assigned to
four groups and were treated with intravenous injection of
AOPP-modified rat serum albumin (RSA) in the presence
or absence of the NADPH oxidase inhibitor apocynin for
5–12 weeks. Plasma AOPP levels increased approximately
onefold in AOPP-RSA-treated rats compared with that in
vehicle- or RSA-treated controls (Table 1). Chronic admin-
istration of AOPP-RSA, but not that of native RSA,
significantly enhanced the renal deposition of AOPPs,
increased urinary albumin excretion, and elevated the
level of urinary 8-OHdG (8-hydroxydeoxyguanosine), a
well-known biomarker of oxidative stress in vivo.1 Interven-
tion of apocynin significantly attenuated albuminuria and
decreased urinary 8-OHdG level in AOPP-challenged rats.
There was no significant difference in serum creatinine levels
among the groups (Table 1).
Podocyte apoptosis increased in AOPP-challenged rats and
was ameliorated by treatment with apocynin
To determine whether AOPP accumulation induces podocyte
apoptosis and to delineate the relationship between apoptosis
and changes in podocyte number, we first quantified rates
of podocyte apoptosis using double-immunofluorescence
labeling, including Wilms’s tumor-1 and terminal deoxy-
uridine nick-end labeling (TUNEL) assay. TUNEL-positive
podocytes per glomerular cross-section were significantly
increased in AOPP-treated rats from week 5 compared
with age-matched control animals (vehicle- or RSA-treated
rats) (Figure 1a and b). Interestingly, apoptosis was
also detectable in tubular epithelial cells, particularly in
AOPP-treated rats (data not shown). Treatment of
apocynin significantly prevented podocytes from AOPP-
induced apoptosis (Figure 1a and b), indicating that
the apoptotic processes are dependent on the activation of
NADPH oxidase.
To further confirm the in vivo proapoptotic effect of
AOPPs on podocytes, we next identified and quantified
podocytes in urine sediments. Podocytes in cytospin urine
sediments were identified as either nucleated or multi-
nucleated cells expressing podocalyxin, using an immuno-
fluorescence microscope. As shown in Figure 1c, no urinary
podocytes were detected in rats treated with vehicle or native
RSA. The mean value of podocytes per milliliter urine among
Table 1 |Metabolic and biochemical parameters of rats at
week 5 and week 12
Parameters Week 5a (n = 10) Week 12a (n = 10)
Body weight (g)
Vehicle 329.24±24.29 396.07±17.50
RSA 325.33±26.06 396.21±13.58
AOPPs 306.60±26.64 388.11±33.42
AOPPs+apocynin 315.89±24.44 390.27±28.99
Systolic blood pressure (mmHg)
Vehicle 118.28±3.47 123.56±3.18
RSA 120.33±4.16 126.45±3.59
AOPPs 121.25±3.79 125.97±4.03
AOPPs+apocynin 120.40±3.75 122.49±4.15
Urinary albumin excretion (mg per 24 h)b
Vehicle 152.95±84.11 163.63±116.63
RSA 205.28±139.35 243.32±130.24
AOPPs 759.69±125.38c 1548.90±324.16c
AOPPs+apocynin 203.52±49.93d 273.86±90.26d
Urinary 8-OHdG excretion (ng per 24 h)e
Vehicle 475.10±178.97 454.86±185.47
RSA 445.04±223.72 488.15±313.82
AOPPs 1346.31±263.56c 2279.34±430.46c
AOPPs+apocynin 827.29±235.82c,d 1076.07±520.22c,d
Serum creatinine (mmol/l)f
Vehicle 35.1±2.1 35.3±3.1
RSA 34.7±4.0 34.3±3.3
AOPPs 35.3±2.6 35.2±4.2
AOPPs+apocynin 35.5±3.3 35.7±2.7
Plasma AOPPs (mmol/l)g
Vehicle 27.72±3.51 27.90±4.31
RSA 26.94±6.83 28.93±7.75
AOPPs 60.92±14.67c 76.87±18.73c
AOPPs+apocynin 43.19±10.66c,d 58.86±10.36c,d
AOPP level in renal tissue (mmol/g protein)g
Vehicle 8.03±1.43 8.16±2.94
RSA 8.11±2.31 9.94±3.62
AOPPs 19.35±3.93c 25.33±6.23c
AOPPs+apocynin 15.65±5.22c,d 18.95±7.68c,d
ANOVA, analysis of variance; AOPP, advanced oxidation protein product; 8-OHdG,
8-hydroxydeoxyguanosine; ELISA, enzyme-linked immunosorbent assay; RSA, rat
serum albumin.
aData are mean±s.d.
bUrinary albumin excretion was measured using an ELISA kit, ANOVA, Po0.001.
cPo0.05 vs vehicle.
dPo0.05 vs AOPPs.
eUrinary 8-OHdG level was analyzed using a commercial kit, ANOVA, Po0.001.
fSerum creatinine was measured by enzymatic assay (CRE-EN, Kynos, Tokyo, Japan).
gAOPP levels in the plasma and in renal tissue were measured as described in
Li et al.24, ANOVA, Po0.001.
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the animals treated with AOPP-RSA was 1.90±1.14 (n¼ 10)
at week 5, with 68% of podocytes being apoptotic (indicated
by positive TUNEL staining). Podocyturia in AOPP-treated
rats appeared from week 3 and attained peak level at week 5
(data not shown). Intervention of apocynin significantly
decreased podocyturia and urinary apoptotic podocytes at
week 5 (Figure 1c–e).
Podocyte loss occurred in AOPP-challenged rats and was
blocked by treatment with apocynin
To examine whether AOPP-induced podocyte apoptosis
results in glomerular podocyte loss, we first examined the
morphological changes in podocytes under electron micro-
scopy. As shown in Figure 2, specific indicators of podocyte
injury,31 including flattening of foot processes, local detach-
ments of foot processes with loss of podocytes, leaving areas
of denuded glomerular basement membrane, and loss of
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Figure 1 |Accumulation of AOPPs induced podocyte
apoptosis and podocyturia. Podocyte apoptosis in the
glomeruli: (a) Representative photographs showing double-
immunofluorescence labeling of WT-1 (red) and TUNEL (green)
in podocytes in the glomeruli from rats treated with or without
AOPP-RSA. (b) Bar graphs show the mean number of WT-1
and TUNEL-positive podocytes per glomerular cross-section.
Apoptotic podocytes in urine: (c). Representative photographs of
triple-fluorescence labeling of urine sediments using Hoechst
nuclear staining (blue), goat anti-rat podocalyxin (PCX) IgG (red),
and TUNEL (green). (d) The mean number of podocytes
(PCX-positive cells) and apoptotic podocytes (PCX and TUNEL-
positive cells) in urine at week 5. (e) Representative double-nuclei
podocyte in urine. Data are shown as mean±s.d., n¼ 10 in each
group. *Po0.01 vs vehicle; #Po0.01 vs AOPPs. AOPP, advanced
oxidation protein product; IgG, immunoglobulin G; RSA, rat serum
albumin; TUNEL, terminal deoxyuridine nick-end labeling; WT-1,
Wilms’s tumor-1.
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Figure 2 |Morphological changes and immunohistochemical
staining of ki-67 and PCNA. (a) Representative electron-
micrographs of rats treated with or without AOPP-RSA (original
magnification: 15,000). Loss or flattening of foot processes, local
detachments leaving behind naked areas of GBM (arrowheads),
and denudation of GBM (arrows) were found in AOPP-treated rats;
these could be largely prevented by apocynin treatment.
(b) Immunohistochemical analysis showed that expression
of ki-67 (bar¼ 100mm) and PCNA (bar¼ 50mm) was located
mainly in tubular epithelial cells. AOPP, advanced oxidation
protein product; GBM, glomerular basement membrane; PCNA,
proliferating cell nuclear antigen; RSA, rat serum albumin.
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entire podocytes were found in AOPP-treated rats, which was
largely ameliorated by treatment with apocynin (Figure 2).
Similarly, podocyte number and podocyte density, as analyzed
using stereological methods, were significantly reduced in
AOPP-treated rats at week 12 compared with controls.
Treatment of apocynin significantly ameliorated the AOPP-
induced podocyte loss in the glomeruli (Table 2).
To determine whether podocyte apoptosis is associated
with cellular regeneration, we examined the expression
of ki-67 and proliferating cell nuclear antigen (PCNA) in
kidney sections. Expression of ki-67 and PCNA was mainly
located in tubular epithelial cells in AOPP-treated animals
(Figure 2).
Increase in extracellular AOPPs was sufficient to trigger
apoptosis of podocytes in vitro by NADPH-dependent
superoxide generation
To further confirm the proapoptotic effect of AOPPs on
the podocyte, cultured murine podocytes were incubated
with indicated concentration of AOPP-modified murine
serum albumin (MSA) for 48 h or treated with 200 mg/ml
of AOPP-MSA for the indicated time. Exposure of podocytes
to AOPP-MSA induced dose- and time-dependent increase in
apoptosis as assessed by Annexin V (AV)-labeled cells. AOPP
fraction isolated from patients with uremia showed a similar
effect on cultured podocytes (Figure 3a). Increased apoptosis
in podocytes incubated with AOPP-MSA was also shown
by analysis of DNA strand breaks with the TUNEL assay
(Figure 3b) and electron microscopic analysis (Figure 3c).
AOPP-induced apoptosis could be largely blocked by treat-
ment of apocynin (Figure 3b and c).
To clarify the underlying mechanism of AOPP-induced
podocyte apoptosis, podocytes were preincubated for 1 h
with the inhibitors of various enzymatic systems involved
in reactive oxygen species generation, a broad spectrum
inhibitor of protein kinase C (PKC) (Go¨6983), and an
intracellular superoxide (O2
) scavenger (cytosolic Cu/Zn
superoxide dismutase, c-SOD), respectively. The cells were
then incubated with AOPP-MSA for 48 h. AOPP-MSA-
induced podocyte apoptosis was significantly suppressed by
the NADPH oxidase inhibitors, DPI (diphenyleneiodonium)
and apocynin, the PKC inhibitor, Go¨6983, and c-SOD, but not
by the inhibitors of nitric oxidase synthase, cyclooxygenase,
xanthine oxidase, and the inhibitors of mitochondrial
respiratory chain complexes, suggesting that AOPP-triggered
podocyte apoptosis is mainly mediated by PKC-NADPH
oxidase-dependent O2
 generation (Figure 3d).
AOPP challenge increased NADPH-dependent O2
 generation
in vitro and in vivo
To further confirm the presence of oxidative stress and
the enzyme source of O2
 in AOPP-challenged podocytes,
oxidase activity in response to the addition of various
substrates was examined in podocyte homogenates. As shown
in Figure 4a, O2
 production derived from NADPH was
greater than that obtained from other potential sub-
strates. NADPH-dependent O2
 production was significantly
enhanced in AOPP-treated podocytes compared with cells
incubated with medium alone or native MSA (Figure 4b).
Furthermore, AOPP-triggered O2
 generation was almost
completely blocked by pretreating podocytes with Go¨6983,
DPI, apocynin, and c-SOD, but not by inhibitors of other
potential enzymes, suggesting that AOPP-triggered O2
 pro-
duction in cultured podocytes is dependent on the activation
of PKC-NADPH oxidase (Figure 4b).
Similarly, O2
 production in renal cortex homogenates was
significantly increased in AOPP-treated rats compared with
that in controls, which could be almost completely inhibited
by pretreatment of the homogenates with DPI or c-SOD
(Figure 4c).
AOPP challenge activated NADPH oxidase in vitro and in vivo
To further investigate the mechanisms underlying the
induction of O2
 by AOPPs, we examined the effect of
AOPPs on the activity of NADPH oxidase. AOPP-MSA
induced rapid phosphorylation of the cytoplasmic subunit
p47phox in cultured podocytes (Figure 5a). AOPP-induced
p47phox phosphorylation could be blocked by pretreatment of
podocytes with a PKC inhibitor, Go¨6983 (Figure 5a).
To examine the interaction of p47phox with the membrane
subunits, we immunoprecipitated p22phox, Nox 2, and Nox 4
with the specific antibodies, and then probed for the
coexistence of p47phox. As shown in Figure 5b, the amount
of p47phox–p22phox complex formation rapidly increased in
AOPP-stimulated podocytes. At 15min after AOPP challenge,
p47phox membrane translocation was apparent (Figure 5c).
AOPPs also promoted the association of p47phox with Nox 2
and Nox 4 (Figure 5d).
The increased expression of NADPH oxidase subunits
might be necessary for its sustained activation. To examine
Table 2 | AOPP challenge reduced podocyte number and glomerular podocyte density
Parameters Vehicle (n=7) RSA (n=7) AOPPs (n=7) AOPPs+Apocynin (n=7) P value
Npodocyte 160.2±22.5 160.7±18.4 130.4±21.0
a 154.4±18.8b o0.05
Vglomerulus 500,999±99,111 521,552±92,691 627,689±95,392
a 59,9019±12,2731 o0.05
Nv (Podo/glom) 0.00033±0.00007 0.00032±0.00008 0.00021±0.00003a 0.00026±0.00003b o0.05
AOPP, advanced oxidation protein product; Npodocyte, mean podocyte number/glomerulus; Vglomerulus, glomerular volume (mm
3); Nv (Podo/glom), numerical density of
podocyte/glomerulus; RSA, rat serum albumin.
Data are mean±s.d.
aPo0.05 vs vehicle.
bPo0.05 vs AOPPs.
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the effect of AOPPs on the expression of the oxidase sub-
units, podocytes were incubated with AOPP-MSA for 1–12 h.
Compared with cells incubated with native MSA, podocytes
treated with AOPP-MSA showed significantly increased
expression of p47phox, Nox 2, and Nox 4, after 3 h of
stimulation (Figure 5e). Similarly, renal cortex homogenates
from the AOPP-treated rats showed a significantly upregu-
lated expression of p47phox and Nox homologs compared
with controls (Figure 5f).
AOPP-induced apoptosis was associated with increased p53
and Bax protein synthesis and caspase-3 activity
Upregulation of p53 has been reported to mediate apoptosis
through Bax protein expression in response to a number
of stress signals.2,32 To examine the potential mediators
of AOPP-induced apoptosis, we analyzed the abundance of
p53 and Bcl-2 family proteins (Bax and Bcl-2) and that of
caspase-3 by western blot analysis. AOPP challenge increased
p53 expression in cultured podocytes from 2 h. Proapoptotic
Bax expression was increased from 6 h (Figure 6a),
followed by a decrease in procaspase-3 levels and increase
in cleaved caspase-3 at 6–48 h of AOPPs treatment (Figure
6b). Levels of intact 113-kDa PARP (poly (adenosine
diphosphate-ribose) polymerase), a substrate of activated
caspases, were decreased from 12 h, coincident with the
appearance of 85-kDa PARP cleavage products (Figure 6b).
These data suggest that AOPP-induced apoptosis is asso-
ciated with increase activity of the p53-Bax–caspase-3
pathway. Enhanced expression of p53 and Bax protein
and activation of caspase-3, could be blocked by the
inhibitors of PKC and NADPH oxidase, suggesting that
AOPP-induced activation of proapoptotic molecules is
mainly mediated by PKC-NADPH oxidase-dependent O2

generation (Figure 6c). Consistent with the in vitro observa-
tion, western blot analysis of the renal cortex homogenates
showed upregulation of p53, Bax, and caspase-3 in AOPP-
treated rats (Figure 6d).
DISCUSSION
Increased recognition of AOPPs, as a class of potential renal
pathogenic mediators and the multiple means by which they
form in diverse disorders, has highlighted the importance of
determining mechanisms by which AOPPs might induce
or promote the progression of glomerulopathy. This study
provided in vivo and in vitro evidence showing that the
accumulation of AOPPs triggers podocyte apoptosis and
results in podocyte depletion through NADPH oxidase-
dependent O2
 generation. AOPP-albumin, but not native
albumin, altered the life span of the podocyte, suggesting that
the triggering effect is due to AOPPs and is not a property of
albumin or other contaminants. To the best of our knowl-
edge, this is the first study showing the role of AOPPs in the
pathogenesis of podocyte depletion.
Podocyte depletion has been proposed as a hallmark of
primary and secondary forms of glomerulosclerosis for many
years.6,33 The extent of podocyte depletion is now considered
a central problem in the progression of both diabetic and
nondiabetic nephropathy.10,12,34,35 Although clinical and
animal studies clearly demonstrate the phenomenon of
podocyte depletion in various glomerular diseases, the
mechanism(s) underlying podocyte loss have not been
completely understood. Podocyte apoptosis has been shown
to be a glomerular phenotype that coincides with the onset
of albuminuria and is associated with progressive podocyte
depletion.14,15 Several factors have been suggested to induce
podocyte apoptosis; hyperglycemia, transforming growth
factor-b, and angiotensin II have been extensively character-
ized.14–17 In this study, we identified AOPP accumulation as
a new candidate mechanism for podocyte apoptosis and
podocyte depletion. As we have reported previously,24,36
chronic administration of AOPP-albumin in normal rats
increased the plasma concentration of AOPPs to the level
that has been found in diabetic plasma and increased AOPP
deposition in the renal tissue. In this model, podocyte
apoptosis developed at week 5 and coincided with the onset
of albuminuria. The in vitro study also showed that both
AOPP-MSA and AOPP fraction isolated from uremic patients
triggered podocyte apoptosis in a dose- and time-dependent
manner. It is noteworthy that, apoptosis of tubular epithelial
cells was also increased in AOPP-treated rats, suggesting
that epithelial cells might be selectively susceptible to AOPP-
induced apoptosis. Interestingly, a recent in vitro study has
also shown that AOPP challenge promotes renal tubular
cells injury through a CD36-dependent pathway.37 Our very
recent finding shows that AOPPs also target mesangial cells,38
suggesting that at least some of the renal pathogenic effects of
AOPPs might be mediated by the mechanism independent of
podocyte lesion.
Importantly, this study shows that AOPP-triggered apop-
tosis is sufficient to induce podocyte loss in vivo. The
Figure 3 |AOPPs triggered apoptosis in cultured podocytes by NADPH oxidase-dependent O2
 generation. (a) Podocytes were
incubated with AOPP-MSA or AOPP fraction (AOPP-F) isolated from uremic patients for indicated time. Apoptotic podocytes, determined
by Annexin V-labeled cells, significantly increased in a dose- and time-dependent manner. *Po0.05 vs medium alone. (b) Representative
photographs showing TUNEL-positive apoptotic cells in cultured podocytes. Apocynin treatment attenuated AOPP-induced podocyte
apoptosis. (c) Representative electron micrographs of podocytes incubated with or without AOPP-MSA (original magnification: 8,000).
Treatment with apocynin attenuated AOPP-induced podocyte apoptosis. (d) Podocytes were preincubated with the inhibitors of
mitochondrial respiratory chain complexes (rotenone; TTFA, and myxothiazol), an inhibitor of nitric oxidase (L-NMMA), a xanthine oxidase
inhibitor (allopurinol), the inhibitors of NADPH oxidase (DPI and apocynin), a O2
 scavenger (c-SOD), and a PKC inhibitor (Go¨6983). The cells
were then incubated with 200mg/ml of AOPP-MSA for 48 h. Apoptosis was quantified by measuring Annexin V-labeled cells using a flow
cytometer. Data are expressed as mean±s.d. of three independent experiments. #Po0.01 vs AOPPs. AOPP, advanced oxidation protein
product; c-SOD, Cu/Zn superoxide dismutase; DPI, diphenyleneiodonium; MSA, murine serum albumin; NADPH, nicotinamide adenine
dinucleotide phosphate; PKC, protein kinase C; TTFA, thenoyltrifluoroacetone; TUNEL, terminal deoxyuridine nick-end labeling.
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following lines of evidence support this conclusion. First,
podocyte apoptosis coincided with the onset of podocyturia
and 68% of urinary podocytes underwent apoptosis.
Consistent with this finding, a previous study indicated that
podocyturia is associated with podocyte loss and progression
of IgA nephropathy, a disorder with the prevalence of AOPP
accumulation.12,26 Second, morphological observation of
the AOPP-challenged kidney showed structural changes in
response to loss of podocytes and denudation of glomerular
basement membrane. Third, reduction in podocyte number
and decreased glomerular podocyte density, as judged by the
unbiased stereological methods, further confirmed the loss
of podocytes in AOPP-treated animals. A progressive deple-
tion of podocytes results in denuded glomerular basement
membrane areas and tuft adhesions that has been considered
as initial lesions of irreversible glomerular damage.39 Further-
more, the inability to undergo cell regeneration after podo-
cyte damage may also result in glomerulosclerosis.40 Taken
together, our finding suggests that accumulation of AOPPs
might be involved in the initiation or progression of CKD by
promoting podocyte depletion. Supporting the notion, our
previous studies have shown that chronic accumulation of
AOPPs promotes renal damage in a diabetic model and
accelerates glomerulosclerosis in the remnant kidney.12,25
In this study, we also showed that AOPP-induced
podocyte apoptosis and depletion are mainly mediated by
NADPH oxidase-dependent superoxide generation. Human
and rodent podocytes express the components of NADPH
oxidase including p47phox, p22phox, and Nox homologs.
NADPH oxidase represents the major source of superoxide
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Figure 5 |AOPP challenge induced activation of NADPH oxidase in vitro and in vivo. (a) Podocytes were incubated with 200 mg/ml
of AOPP-MSA or native MSA for indicated time. Phosphorylation of p47phox was assayed by immunoprecipitation (IP) using an a-p47phox
and detected by immunoblotting (IB) using an a-pan-p47phox and an a-phosphoserine as the primary antibodies. (b) AOPP-induced binding
of p47phox to p22phox. Podocytes were treated as described above. IP was performed using an a-p22phox, and IB was conducted using
an a-p47phox. (c) Representative photographs of AOPP-induced membrane translocation of p47phox. Podocytes were incubated with an
a-p47phox, then with an FITC-conjugated secondary antibody and counterstained with Hoechst 33258 (bar¼ 30mm). (d) Interaction of
p47phox with Nox 2 and Nox 4. Podocytes were treated as described above. IP was performed using an a-Nox 2 or an a-Nox 4. IB was
conducted using an a-p47phox. (e) Expression of NADPH oxidase subunits in cultured podocytes. Podocytes were incubated with or without
AOPPs for 1–12 h. Protein expression of NADPH oxidase was determined by western blot using the antibodies against the subunits of
NADPH oxidase. (f) Expression of NADPH oxidase subunit protein in the renal cortex at week 5 was analyzed as described above. Data are
expressed as mean±s.d. of three independent experiments (in vitro experiments) or of five animals per group (in vivo experiments).
*Po0.05 vs medium alone (in vitro experiments) and vehicle (in vivo experiments). #Po0.05 vs AOPPs. AOPP, advanced oxidation protein
product; FITC, fluorescein isothiocyanate; MSA, murine serum albumin; NADPH, nicotinamide adenine dinucleotide phosphate.
Figure 4 |AOPP challenge increased NADPH-dependent O2

production in cultured podocytes and in the renal cortex.
(a) O2
 production in response to the addition of various
substrates (NADPH, NADH, xanthine, succinate, and arachidonic
acid) was determined in podocyte homogenates using the
lucigenin chemiluminescence method. (b) Podocytes were
pretreated with the inhibitors of various enzymes and then
incubated with AOPP-MSA. AOPP-triggered O2
 generation was
almost completely blocked by pretreatment with the inhibitors
of PKC and NADPH oxidase, as well as c-SOD. (c) O2
 production in
the renal cortex, determined by the lucigenin counts, significantly
increased in AOPP-treated rats compared with controls.
AOPP-induced O2
generation was inhibited by pretreatment
of renal homogenates with DPI or c-SOD. Data are expressed
as mean±s.d. of three independent experiments. *Po0.05 vs
medium alone; #Po0.01 vs AOPPs. AOPP, advanced oxidation
protein product; CPS, counts per second; c-SOD, Cu/Zn
superoxide dismutase; DPI, diphenyleneiodonium; NADH,
nictinamide adenine dinucleotide; NADPH, nicotinamide adenine
dinucleotide phosphate; PKC, protein kinase C.
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generation in both cultured podocytes and in the renal
cortex.39,41 In this study, we first showed that AOPP challenge
induced overproduction of O2
 in cultured podocytes and
in the in renal cortex. AOPP-induced O2
 production was
NADPH dependent and could be blocked by the inhibitors
of NADPH oxidase. Next, we examined the activity of
NADPH oxidase in AOPP-challenged podocytes. Exposure of
podocytes to AOPPs induced rapid phosphorylation of the
cytoplasmic subunit p47phox and its membrane translocation;
this was followed by increased interaction of p47phox with the
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membrane subunits p22phox, Nox 2, and Nox 4, confirming
the activation of total oxidase in AOPP-triggered podocytes.
Furthermore, we showed that expression of the key subunits
of NADPH oxidase, including that of p47phox, p22phox, Nox 2,
and Nox 4, was upregulated in cultured podocytes after 3 h of
exposure to AOPPs. Overexpression of these NADPH oxidase
subunits was also found in the renal cortex of rats treated
with AOPPs. Finally, we provided data showing that AOPP-
induced apoptosis could be largely blocked by pretreating
podocytes with the NADPH oxidase inhibitors and the
intracellular O2
 scavenger in vitro, or by the intervention
of apocynin in vivo. Oxidant-dependent DNA damage in
podocytes has also been found in puromycin amino-
nucleoside-treated rats.18 These data suggest that NADPH
oxidase-dependent O2
 generation constitutes a major path-
way resulting in AOPP-induced podocyte apoptosis. This
was validated in principle in vivo after the chronic inhibition
of NADPH oxidase in diabetic models.25,42,43 The patho-
physiological relevance of NADPH oxidase activation in the
induction of renal oxidative stress is further supported by the
observation of increased urinary 8-OHdG.
Activation of NADPH oxidase occurs through multiple
signaling pathways;44 however, several studies have demon-
strated a critical role of PKC.1,45,46 In this study, a broad
spectrum inhibitor of PKC (Go¨6983) inhibited AOPP-
induced NADPH oxidase activation and O2
 production,
and blocked subsequent apoptosis in cultured podocytes,
suggesting that PKC may be located upstream of oxidase
activation in the signaling pathway that leads to AOPP-
induced O2
 production.
Both podocyte growth and apoptosis are complexly
regulated by the Bcl-2 family, including both proapoptotic
molecules (such as Bax) and antiapoptotic molecules (such
as Bcl-2). These molecules are regulators of caspases, which
serve as the terminal effectors molecules in many types of
apoptosis.47 In this study, we found that AOPP challenge
increased p53 accumulation in podocytes. Furthermore,
the expression of proapoptotic molecule Bax protein and
the activity of effector caspase-3 were significantly increased
by treatment with AOPPs. As p53 has been reported
to mediate programmed cell death through Bax protein
expression in response to a number of stress signals,2,32
AOPP challenge might induce apoptosis in the podocyte
through p53-dependent Bax expression. It is noteworthy
that the kinetic profile in this study showed significant
induction of O2
 content as early as 0.5 h; this was followed
by the upregulation of p53 after 2 h of exposure and
increased expression of Bax after 6 h of incubation. More-
over, the AOPP-triggered p53-Bax-caspase pathway could be
almost completely blocked by c-SOD and NADPH oxidase
inhibitor, suggesting that the proapoptotic pathway is
activated by superoxide produced by NADPH oxidase
activation.
In summary, we conclude that accumulation of AOPPs
promotes podocyte depletion by the induction of podocyte
apoptosis, which is mainly mediated by NADPH oxidase-
dependent O2
 generation. Given that AOPP accumulation
is prevalent in diverse pathophysiological conditions such
as diabetes, metabolic syndrome, and CKD, this finding
might be highly significant because it might be an impor-
tant step toward understanding the renal pathogenic effects
of AOPPs and may provide new targets for the prevention of
progressive glomerulosclerosis seen in these disorders.
MATERIALS AND METHODS
AOPP-albumin preparation
AOPP-RSA and AOPP-MSA were prepared in vitro by incuba-
tion of RSA or MSA (Sigma Chemical, St Louis, MO, USA) with
200mmol/l of hypochlorous acid (Fluke, Buchs, Switzerland) in the
absence of free amino acid/carbohydrates/lipids to exclude the
formation of advanced glycation end products–like structures.19,24
Prepared samples were dialyzed against phosphate-buffered saline to
remove free hypochlorous acid. AOPP fraction formed in vivo was
isolated from the serum of patients with uremia using HiPrep 16/60
Sephacryl S-300HR column (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) as described previously.48 The concentration of
AOPP fraction in patients’ serum was B200 mg/ml.48 All samples
were passed through a DetoxiGel column (Pierce, Rockford, IL,
USA) to remove contaminated endotoxin. The endotoxin levels in
the preparations were tested using the Amebocyte Lysate Kit (Sigma
Chemical) and were found to be o0.025 EU/ml.
AOPP content in the preparation, as determined by the
absorbance of the reaction mixture of the samples and acetic
acid,19,24 was 56.4±4.3 nmol/mg protein in AOPP-RSA, 73.6±
8.4 nmol/mg protein in AOPP-MSA, 0.30±0.03 nmol/mg protein
in native RSA, and 0.25±0.02 nmol/mg protein in native MSA.
The components of advanced glycation end products were
undetectable in the prepared samples.49–51
Cell culture
Murine podocytes were generously provided by Professor Peter
Mundel (Sinai School of Medicine, New York, NY, USA) and cultured
as described previously.52 Undifferentiated podocytes were grown in
RPMI 1640 containing 10% fetal bovine serum, penicillin (100U/ml),
streptomycin (100mg/ml), sodium pyruvate (1mmol/l), HEPES
buffer (10mmol/l), and sodium bicarbonate (0.075%) (all obtained
from Sigma Chemical). To passage the cells, podocytes were grown
under ‘growth-permissive’ conditions, which involved growing cells at
33 1C in the presence of interferon-g (50U/ml, Sigma Chemical). For
Figure 6 |AOPP challenge increased p53 and Bax protein synthesis and caspase-3 activity. (a) The abundance of p53, Bax, and Bcl-2
in podocytes incubated with or without AOPPs was determined by western blot. AOPP challenge increased p53 expression in cultured
podocytes from 2h and Bax protein synthesis from 6h. (b) AOPP challenge decreased procaspase-3 levels and increased cleaved caspase-3
at 6–48 h of exposure. Levels of intact 113-kDa PARP were decreased from 12 h in AOPP-treated podocytes. (c) AOPP-induced upregulation
in p53, Bax, and activity of caspase-3 could be blocked by pretreatment of podocytes with Go¨6983, DPI, and c-SOD. (d) Upregulation of p53,
Bax, and caspase 3 in the renal cortex homogenates from rats treated with AOPPs. Data are shown as mean±s.d. of three independent
experiments. *Po0.05 vs medium alone; #Po0.05 vs AOPPs. AOPP, advanced oxidation protein product; Bax, p53- and Bcl-2-associated X;
c-SOD, Cu/Zn superoxide dismutase; DPI, diphenyleneiodonium; PARP, poly (adenosine diphosphate-ribose) polymerase.
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podocytes to acquire a differentiated phenotype, cells were grown
under ‘restrictive conditions’ at 37 1C in the absence of interferon-g
for more than 12 days. Experiments were carried out using passages
10–18, growth-restricted, conditionally immortalized podocytes.
Animal studies
Male Sprague–Dawley rats (initial weight, 180–200 g, Southern Medical
University Animal Experiment Center, Guangzhou, China) were
housed in a standard environment with free access to water and diet.
The rats were randomly assigned to four groups (n¼ 10 in each group)
and received daily intravenous injection of vehicle (phosphate-buffered
saline, pH 7.4), native RSA (100mg/kg per day), AOPP-RSA (100mg/
kg per day), and AOPP-RSA (100mg/kg per day) with intragastric
administration of apocynin (Sigma Chemical, 100mg/kg per day),
separately.50 The dosages of AOPPs and the internal injection were
based on our preliminary studies, in which plasma AOPP levels
increase approximately onefold of the normal concentration in rats (the
level that has been found in patients with diabetes).24,25
The rats were killed at the end of weeks 5 and 12. Their kidneys
were collected after perfusion with 50ml of ice-cold normal saline.
AOPP levels in the plasma and renal cortex homogenate were
measured as described above.
Assessment of podocyte apoptosis
AV-labeled cells in cultured podocytes. Determination of
AV-labeled apoptotic cells was performed as described previously.53
Cell suspension was incubated with either fluorescein isothiocyanate
(FITC)-conjugated AV alone, propidium iodide (PI) alone, or a
combination of both according to the manufacturer’s instructions
(KeyGen, Nanking, China). Cells were analyzed using a flow cyto-
meter (BD FACSCalibur System, Franklin Lakes, NJ, USA), with
excitation at 488 nm and emission at 525 nm (for AV-labeled cells)
and 620 nm (for PI-labeled cells). Single labeling was used to gate
and control for bleed through. Cell population was characterized
on the basis of whether it was labeled with neither AV nor PI
(viable), AV alone (apoptotic), PI alone (necrotic), or both AV and
PI (late apoptotic).
TUNEL assay in cultured podocytes. DNA strand breaks in
cultured podocytes were identified using TUNEL as described previ-
ously.49 The cells were fixed in 4% paraformaldehydrate
followed by methanol. After washing, cells were incubated in TDT
buffer containing the TdT enzyme and FITC-conjugated
dUTP according to the manufacturer’s protocol (KeyGen).
Morphological changes in cells undergoing apoptosis were
detected simultaneously by counterstaining them with Hoechst
33258 (KeyGen, Nanking, China). The slides were examined by
fluorescent microscopy (Leica TCS SP2 AOBS, Leica Microsystems,
Cambridge, UK).
Analysis of podocyte apoptosis in renal tissue. Apoptotic cells
were detected on frozen kidney section using FITC-labeled in situ
Apoptosis Detection Kit (KeyGen, Wuhan, China). For identifica-
tion of the apoptotic podocyte, tissue sections were costained with
anti-Wilms’s tumor-1 antibody (red) and TUNEL (green). The cells
double labeled by Wilms’s tumor-1 and TUNEL were counted as
apoptotic podocytes.
Identification of apoptotic podocytes in urine. Rat sterile
urine was collected by bladder puncture as described previously.54
Resuspended cell pellets were centrifuged onto polylysine-coated
slides, fixed with 3% paraformaldehyde, and then permeabilized with
Triton X-100. After blocking with 1% bovine serum albumin, the
slides were incubated with a goat anti-rat podocalyxin anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and then
with the secondary antibody TRITC-labeled donkey anti-goat IgG
(Santa Cruz Biotechnology). The sediments were counterstained with
Hoechst nuclear stain to distinguish whole cells from cell fragments.
TUNEL staining for apoptosis was performed on the specimens using
a standard FITC incorporation kit (KeyGen) according to the package
instructions. The slides were examined using a fluorescence
microscope (BX51, Olympus, Tokyo, Japan) at 590 nm for podoca-
lyxin, 488 nm for TUNEL, and 460nm for Hoechst. Nucleated,
podocalyxin-positive cells were considered to be detached podocytes
and those with a positive staining of FITC were regarded as apoptotic
podocytes. Urinary podocyte number was quantified in a blinded
manner and was shown as cells per milliliter urine.
Expression of apoptosis-related molecules. To measure the
protein expression of apoptosis-related molecules, cultured cells
were lysed and the frozen renal cortex was processed for protein
extraction as described previously.55 The protein samples were
subjected to 8–12% SDS-PAGE before being transferred into PVDF
(polyvinylidene fluoride) membranes (NEN Life Science Products,
Boston, MA, USA). Western blotting was performed as described
elsewhere56 using the following primary antibodies: anti-p53mAb
(Oncogene Research Products, San Diego, CA, USA), anti-Bax mAb
(Santa Cruz Biotechnology), polyclonal rabbit anti-caspase-3 (Cell
Signaling Technology, Beverly, MA, USA), anti-Bcl-2mAb (Santa
Cruz Biotechnology), and anti-PARP mAb (Cell Signaling Techno-
logy). Bound primary antibodies were detected with horseradish
peroxidase (HRP)-labeled anti-mouse or anti-rabbit secondary
antibodies, and visualized using enhanced chemiluminescence
reagents (Pierce Chemical, Bockford, IN, USA).
Morphological observation
Renal cortex or podocyte sediment was processed through a primary
and a secondary fixation, acetone dehydration, and then Epon-
Spurr’s resin infiltration as described previously.57 Samples were
rocked overnight and then embedded and polymerized at 60 1C for
24 h. Thin sections (80 nm) were collected and stained with uranyl
acetate and lead citrate. A transmission electron microscope
(Hitachi, Tokyo, Japan) was used to observe the samples.
Immunohistochemical analysis of ki-67 and PCNA
The expression of ki-67 and PCNA in the kidney section was
determined as described previously.58,59 The sections of paraffin-
embedded tissues were rehydrated in phosphate-buffered saline
and subjected to microwave heating. The sections were stained by
monoclonal anti-ki-67 antibody (Dako, Carpinteria, CA, USA) or
monoclonal mouse anti-rat PCNA antibody (Boster, Wuhan, China)
and then detected using the Vectastain Elite ABC Kit (Vector
Laboratories, Burlingame, CA, USA).
Determination of podocyte number and density in
the glomerulus
Sections of 1-mm thickness from the Spurrs blocks were used for the
studies. After facing the block, the first intact section was saved and
numbered 0. At least 200 serial sections were then cut from each
kidney. Every 19th and 20th section was saved together on a slide so
that at least 10 pairs of sections were available for analysis from each
rat. All sections were stained with 1% toluidine blue. The first five
glomeruli not present in section 0, but appearing and disappearing in
subsequent sections, were mapped to a location within the sections
and were numbered 1–5. An Olympus BX51 microscope, fitted with a
digital camera and DP Controller software (Olympus, Tokyo, Japan)
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was used to obtain images of the all sections containing glomeruli
1–5. The  100 oil lens was used giving a final image magnification
of 1680. Adobe Photoshop version CS3 (Adobe Systems Incorpo-
rated, San Jose, CA, USA) was used to observe images.
The number of podocyte (Npodocyte) was counted using
the Disector/Fractionator technique as described previously.60–62
Glomerular volume (Vglomerulus) was measured using the Cavalieri
principle as described elsewhere.61–63 The numerical density of
podocyte per glomerulus (Nv (Podo/glom)) was calculated using
the equation, Nv (Podo/glom)¼Npodocyte/Vglomerulus.
Estimation of NADPH oxidase activity
NADPH-dependent O2
 production. NADPH-dependent O2

production by homogenates from cultured podocytes or the renal
cortex was assessed by lucigenin-enhanced chemiluminescence as
described previously.64 The chemiluminescence value was recorded
every minute for 30min (Victor V Wallac 1420, Perkin-Elmer,
Turku, Finland). The readings in each of the last 5min were
averaged and expressed as counts per second.
P47 phox phosphorylation. Phosphorylation of P47phox in cultured
podocytes was detected by immunoprecipitation as described previ-
ously.65 Briefly, the cell lysates were preabsorbed with protein A/G
agarose beads (Santa Cruz Biotechnology) and incubated with a
polyclonal rabbit anti-p47phox antibody (Santa Cruz Biotechnology).
The immunocomplexes were resolved with SDS-PAGE, transferred
into nitrocellulose membranes (Amersham Pharmacia Biotech,
Piscataway, NJ, USA), and incubated with a HRP-conjugated rabbit
anti-phosphoserine antibody (Stressgen Bioreagents, Victoria, BC,
Canada). The blots were detected with ECL (Pierce). To determine
pan-p47phox, the membranes were washed with an elute buffer, reacted
with an anti-p47phox mAb (BD Biosciences Pharmingen,
San Diego, CA, USA), and subsequently detected with HRP-conjugated
rabbit anti-mouse IgG (DakoCytomation, Glostrup, Denmark) and
ECL. Bands were quantified by densitometry (Universal Hood. 2,
BioRad, Milan, Italy), and values were normalized to the amount of
total p47phox per sample.
Interaction of p47 phox with p22 phox and Nox homologs. The
interaction of p47phox with p22phox and Nox homologs in cultured
podocytes was analyzed by immunoblotting as described previ-
ously.66 The immunocomplexes were obtained by incubation of
cell lysates with a rabbit anti-mouse p22phox, a goat anti-mouse
Nox 2, or a rabbit anti-mouse Nox 4 antibody (all from Santa Cruz
Biotechnology), separately. Immunoblotting was performed using
the rabbit anti-mouse p47phox antibody (Santa Cruz Biotechnology)
as the primary antibody and the HRP-conjugated swine anti-rabbit
IgG (DakoCytomation) as the secondary antibody. The membranes
were detected by ECL. To determine the total p22phox, Nox 2, or
Nox 4, the membranes were eluted and incubated with the
anti-mouse p22phox, Nox 2, or Nox 4 antibodies and then detected
with the HRP-conjugated anti-rabbit or goat IgG antibody
(DakoCytomation).
P47 phox membrane translocation. Cultured podocytes were fixed
in acetone–methanol (1:1, vol/vol). After washing and blocking, the cells
were incubated overnight with a rabbit anti-mouse p47phox antibody at
4 1C. After washing, the slides were incubated with a FITC-conjugated
swine anti-rabbit IgG (DakoCytomation) antibody for 45min at 37 1C,
washed, stained with Hoechst (KeyGen) and observed under a confocal
microscopy (Leica TCS SP2 AOBS, Leica Microsystems).
Expression of NADPH oxidase subunits. Membrane proteins
were extracted using a ProteoExtract kit (Calbiochem, San Diego,
CA, USA) according to the manufacturer’s instructions. Expression
of NADPH oxidase subunits in the membrane and cytosolic fraction
was analyzed by western blot as described elsewhere.67 The primary
antibody was a rabbit anti-p47phox, a rabbit anti-p22phox, a goat
anti-Nox 2, or a rabbit anti-Nox 4 antibodies (all from Santa Cruz
Biotechnology). The secondary antibody was a HRP-conjugated
anti-rabbit or anti-goat IgG antibody.
Statistical analysis
All experiments were carried out in triplicate. Continuous variables,
expressed as mean±s.d., were compared using one-way ANOVA
(analysis of variance). Pairwise comparisons were evaluated by
the Student–Newman–Keuls procedure or Dunnett’s T3 procedure
when the assumption of equal variances did not hold. The Dunnett
procedure was used for comparisons between reference group
and other groups. A two-tailed P-value of o0.05 was considered
statistically significant. Statistical analyses were conducted using
SPSS 13.0 (SPSS Inc., Chicago, USA).
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